On June 7th the first site of the QuiremSpheres® Observational Study, the Universitätsklinikum Carl Gustav Carus in Dresden, Germany, was opened for registration. The observational study aims to further confirm treatment safety and efficacy using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases. We are confident more sites will follow soon, gathering valuable data for further establishing the holmium-166 based QuiremSpheres® as a unique treatment option for these patient groups.

Find more information on clinicaltrials.gov.

Categories: News